This inventor holds 1 USPTO granted patent. Top assignees: Gosudarsvenny Nauchy Tsentr Rossiiskoi Federatsii 'Niopik', Institut Elementoorganicheskikh Soedineny Rossiiskoi Akademii Nauk, Moskovsky Naucho-Issledovatelsky Onkologichesky Institut. Active years: 1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999
Title: Nadezhda Jurievna Krainova: Innovator in Tumor Suppression
Introduction
Nadezhda Jurievna Krainova is a distinguished inventor based in Moscow, Russia. With a significant contribution to the field of cancer research, she has developed a promising agent for suppressing tumor growth. Her innovative approach has the potential to enhance therapeutic options in oncology, making her a vital figure in the scientific community.
Latest Patents
Nadezhda holds one patent for her remarkable invention: an agent for suppressing tumor growth. This development reflects her dedication to advancing medical science and improving patient outcomes in the fight against cancer.
Career Highlights
Krainova has worked with prestigious institutions, notably the Institute of Elemento-Organic Compounds of the Russian Academy of Sciences and the State Scientific Center of the Russian Federation, "Niopik." Her career showcases a commitment to research and innovation, contributing significantly to her field.
Collaborations
Throughout her career, Nadezhda has collaborated with notable professionals, including Mark Efimovich Volpin, a deceased scientist, and Georgy Nikolaevich Vorozhtsov. These partnerships have facilitated knowledge exchange and fostered advancements in their shared research endeavors.
Conclusion
Nadezhda Jurievna Krainova stands out as an influential inventor in the realm of tumor suppression. Her pioneering work and collaborations highlight the importance of innovation in advancing medical research. As she continues to inspire future generations of scientists, her contributions will undoubtedly leave a lasting impact on oncology and beyond.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile